HealthQuiet 29d · day 29
FDA approves breakthrough cancer drug six months ahead of schedule
Trials showed the medication nearly doubled median survival compared to chemotherapy, prompting accelerated approval.
What to know
- FDA accelerated approval of cancer drug by six+ months based on trial data
- Drug nearly doubled median survival: 13.2 months vs. 6.7 months with chemotherapy
- Approval described as reflecting unprecedented trial results
“The FDA approved the medication more than six months ahead of schedule after trials showed it nearly doubled median survival to 13.2 months versus 6.7 months with chemotherapy.”
AL.com · AL.com
FDA Regulatory authority
The record 1 articles and posts · last 29 days